ASA DAILY LOW DOSE 81 MG
ACETYLSALICYLIC ACID : 81 MG · DIN 02394790 · PHARMASCIENCE INC
Health Canada status: MARKETED
What is ASA DAILY LOW DOSE?
ASA DAILY LOW DOSE 81 MG contains ACETYLSALICYLIC ACID : 81 MG. It is listed in the Health Canada Drug Product Database under DIN 02394790, held by PHARMASCIENCE INC, supplied as TABLET (CHEWABLE) for ORAL administration. Health Canada currently lists it as marketed, status dated 01-May-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ASA DAILY LOW DOSE used for?
Pain, fever, inflammation; reducing vascular mortality in suspected acute MI; prevention of first non-fatal MI; unstable angina; TIA/secondary prevention of cerebral infarction; VTE prophylaxis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02394790 |
|---|---|
| Brand name | ASA DAILY LOW DOSE |
| Generic / active ingredient | ACETYLSALICYLIC ACID : 81 MG |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 81 MG |
| Dosage form | TABLET (CHEWABLE) |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | B01AC06 ACETYLSALICYLIC ACID |
| AHFS class | 28:08.04.24 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-May-2013 |
| Original market date | 2013-05-01 00:00:00 |
How is it administered?
Analgesic/Antipyretic: 325-650mg every 4-6h. Platelet aggregation: 81-325mg daily. Acute MI: 162mg chewed immediately, then 162mg maintenance. Take with liquid, preferably after meals.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly specified in provided text (Section 11 header present but content truncated).
How is it supplied?
Bottles of 30, 100 and 120 tablets.
Contraindications
Hypersensitivity to ASA/NSAIDs; acute or history of GI ulcers; hemorrhagic diathesis; severe hepatic, renal, or heart failure; asthma history via salicylates/NSAIDs; methotrexate >=15mg/week; pregnancy T3.
Warnings and precautions
Risk of GI bleeding/ulcers; Reye’s syndrome in children; bleeding risk in surgery; potential for bronchospasm/asthma; caution in G6PD deficiency and gout. Keep out of reach of children.
What can be used instead?
Other Canadian products sharing ATC code B01AC06 ACETYLSALICYLIC ACID. 12 of 23 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ASA | 81 MG | TABLET (DELAYED-RELEASE) | PHARMASCIENCE INC | MARKETED | DIN 02433044 |
| ASA 81 MG | 81 MG | TABLET (DELAYED-RELEASE) | VITA HEALTH PRODUCTS INC | MARKETED | DIN 02372177 |
| ASA 81 MG | 81 MG | TABLET (DELAYED-RELEASE) | PHARMASCIENCE INC | MARKETED | DIN 02244993 |
| ASPIRIN 81MG | 81 MG | TABLET (ENTERIC-COATED) | BAYER INC | MARKETED | DIN 02237726 |
| ASPIRIN 81MG QUICK CHEWS | 81 MG | TABLET (CHEWABLE) | BAYER INC | MARKETED | DIN 02289970 |
| ENTERIC COATED DAILY LOW DOSE ASA 81 MG | 81 MG | TABLET (DELAYED-RELEASE) | VITA HEALTH PRODUCTS INC | MARKETED | DIN 02363127 |
| ENTROPHEN | 81 MG | TABLET (DELAYED-RELEASE) | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 02242281 |
| ENTROPHEN CHEWABLE | 81 MG | TABLET (CHEWABLE) | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 02243974 |
| JAMP-ASA 81MG EC | 81 MG | TABLET (ENTERIC-COATED) | VITA HEALTH PRODUCTS INC | MARKETED | DIN 02427206 |
| PRAXIS ASA EC 81 MG DAILY LOW DOSE | 81 MG | TABLET (DELAYED-RELEASE) | PHARMASCIENCE INC | MARKETED | DIN 02283700 |
Who else supplies ACETYLSALICYLIC ACID worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ACETYLSALICYLIC ACID appears in 11 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.